Assembly Biosciences Inc (ASMB) Q1 2018 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q1 2018 10-Q quarterly report on May 7, 2018 for the quarter ended Mar 31, 2018.

AI summary of MD&A and risk factor updates

Collaboration revenue $3.6M, up from $0.7M YoY, driven by Allergan activity and reimbursements
Net loss $16.2M vs $13.9M YoY, with R&D expense $12.0M vs $9.6M
HBV-cure R&D $1.6M increase, exceeding Microbiome R&D increase of $0.9M
Operating cash flow $(15.5)M vs $35.0M YoY, reflecting prior-year $49.3M deferred-revenue contribution
Cash, equivalents and marketable securities expected to fund operations at least twelve months; Phase 2a studies expected mid-2018

No material changes identified relative to the 10-K
Regulatory approval risk: no NDA or BLA submitted, with product candidates still in early clinical or nonclinical development
Clinical risk: Phase 1a/1b adverse events included headaches, rashes, and one Grade 3 rash causing the only discontinuation
Operational risk: reliance on third-party manufacturers for ABI-H0731, ABI-H2158, and Microbiome materials
Financial risk: approximately $267.3 million accumulated deficit as of March 31, 2018 and funding expected for at least twelve months

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.